Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy.
Am J Physiol Heart Circ Physiol
; 322(1): H87-H93, 2022 01 01.
Article
in English
| MEDLINE | ID: covidwho-1566407
ABSTRACT
The 2019 coronavirus disease (COVID-19) is the disease caused by SARS-CoV-2 infection. Although this infection has been shown to affect the respiratory system, a high incidence of thrombotic events has been observed in severe cases of COVID-19 and in a significant portion of COVID-19 nonsurvivors. Although prior literature has reported on both the coagulopathy and hypercoagulability of COVID-19, the specifics of coagulation have not been fully investigated. Observations of microthrombosis in patients with COVID-19 have brought attention to potential inflammatory endothelial injury. Von Willebrand factor (VWF) and its protease, A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13), play an important homeostatic role in responding to endothelial injury. This report provides an overview of the literature investigating the role the VWF/ADAMTS13 axis may have in COVID-19 thrombotic events and suggests potential therapeutic strategies to prevent the progression of coagulopathy in patients with COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Blood Coagulation Disorders
/
Von Willebrand Factor
/
ADAMTS13 Protein
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Am J Physiol Heart Circ Physiol
Journal subject:
Cardiology
/
Physiology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS